Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Petri, Michelle; J. Wallace, Daniel; Spindler, Alberto; Chindalore, Vishala; Kalunian, Kenneth; Mysler, Eduardo; Michael Neuwelt, C.; Robbie, Gabriel; I. White, Wendy; W. Higgs, Brandon; Yao, Yihong; Wang, Liangwei; Ethgen, Dominique; Greth, Warren

doi:10.1002/art.37824

Public

Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Shared by NobleBlocks on Mar 28, 2013 • 12:00 AM UTC

Authors:

Michelle Petri

Daniel J. Wallace

Alberto Spindler

Abstract

Abstract Objective To evaluate the safety and tolerability of multiple intravenous (IV) doses of sifalimumab in adults with moderate‐to‐severe systemic lupus erythematosus (SLE). Methods In this multicenter, double‐blind, placebo‐controlled, sequential dose‐escalation study, patients were randomized...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!